Form 4: Serina Therapeutics CSO Sells Shares Post-Option Exercise

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, executed a pre-planned sale of 3,398 common shares after exercising stock options.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. [SER], reported a transaction on November 5, 2025.
• The transaction involved the exercise of 3,398 stock options at an exercise price of $0.06 per share.
• Immediately following the exercise, 3,398 shares of common stock were sold at a weighted average price of $4.24 per share.
• The sale price ranged from $4.225 to $4.30 per share.
• This transaction was conducted pursuant to a Rule 10b5-1(c) pre-planned contract, instruction, or written plan.
• Following these transactions, Mr. Moreadith beneficially owns 0 shares of common stock and 397,686 stock options.

Sentiment

Score: 5

Explanation: The transaction is neutral to slightly negative. While it's an insider sale, the fact it's under a 10b5-1 plan mitigates concerns about immediate negative sentiment. The officer still holds a substantial number of options.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on immediate insider information.
• The Chief Scientific Officer retains a significant number of stock options (397,686), maintaining an incentive alignment with shareholders.

Negatives

• An insider, specifically the Chief Scientific Officer, sold shares, which can sometimes be interpreted as a lack of confidence, although mitigated by the 10b5-1 plan.
• The sale price of $4.24 is significantly higher than the exercise price of $0.06, indicating a profitable transaction for the insider.

Risks

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, potentially leading to short-term price pressure.
• The market might interpret the sale as a signal, regardless of the 10b5-1 plan, potentially impacting investor sentiment.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions are a routine part of executive compensation and personal financial planning across all industries, including biotechnology. While a sale can sometimes raise questions, the use of a 10b5-1 plan is a common practice to manage personal finances while adhering to insider trading regulations, particularly in industries with frequent material non-public information.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• Randall Moreadith, Chief Scientific Officer, engaged in a transaction involving the exercise of stock options and subsequent sale of common stock of Serina Therapeutics, Inc. This is considered a related party transaction as it involves a company insider.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, potentially leading to short-term price fluctuations, though the 10b5-1 plan mitigates the negative implications.
• Employees: No direct impact mentioned, but general market sentiment can affect employee morale.

Next Steps

• This filing does not mention any specific future actions, events, or milestones for the company.

Key Dates

Recommendation

While insider selling can be a negative signal, this transaction was executed under a pre-planned Rule 10b5-1 plan, which suggests it was for personal financial management rather than a reaction to new, negative company information. The Chief Scientific Officer still holds a significant number of options, indicating continued alignment with shareholder interests. Therefore, this single transaction does not warrant a change from a 'hold' recommendation without further company-specific news or broader market context.

Keywords

Serina Therapeutics, SER, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Randall Moreadith, Chief Scientific Officer, 10b5-1 Plan, Biotechnology, Pharmaceuticals